Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized comparative study of ipragliflozin combination therapy and sitagliptin combination therapy in patients with type 2 diabetes administrating metformin

Next Previous
Trial Profile

Randomized comparative study of ipragliflozin combination therapy and sitagliptin combination therapy in patients with type 2 diabetes administrating metformin

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipragliflozin (Primary) ; Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms NISM Study

    • Most Recent Events

    • 29 Jun 2021 Results (n=87) of post-hoc analysis of a 52-week of the NISM Study, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
    • 16 Jun 2020 Primary endpoint (Comparison of percentage of patients who achieve the following items 52 weeks after randomization) has not been met, as per Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
    • 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top